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1To the Editor: The prevalence of anemia in patients with New York
Heart Association (NYHA) functional class IV heart failure (HF)
approaches 80% (1). Iron deficiency (ID) has been reported as the
cause of anemia in more than 70% of advanced HF patients (2). The
underlying mechanisms of ID in advanced HF are multiple and
complex. In the majority of these patients, a clear cause of ID such as
gastrointestinal blood loss is not identified. In anemia of chronic
disease, there is abnormal iron bioavailability due to decreased
duodenal absorption, entrapment in the reticuloendothelial system,
and block of iron’s release from iron stores, resulting in less iron for
erythropoiesis. Therefore, although ID represents the cause of anemia
development in HF, chronic disease seems to be the underlying
pathophysiological mechanism.
Thus, it is not known whether severely ill patients are likely to
respond to iron alone, or addition of erythropoiesis-stimulating
agents (ESA) is also necessary. The present study was designed to
assess the magnitude and time course of the hematologic response
to treatment with the combination of erythropoietin and intrave-
nous iron versus intravenous iron alone, in iron-deficient anemic
patients with advanced-stage HF. Forty-three consecutive anemic
patients with advanced HF due to ischemic or dilated cardiomy-
opathy, recently hospitalized for HF decompensation, were
screened. Anemia was defined as serum hemoglobin (Hgb)
12 g/dl in men and 11.5 g/dl in women. All patients
underwent the standard diagnostic workup, including bone mar-
row aspiration, to determine the cause of their anemia. Thirty
patients identified with ID (mean age: 57.3  11.7 years, NYHA
functional class: 3.3  0.8, VO2 at peak exercise: 13.5  4.9
ml/kg/min, left ventricular ejection fraction: 24  6.9%, left
ventricular end-diastolic diameter: 71.8  8.0 mm, pulmonary
apillary wedge pressure: 25.4  9.2 mm Hg, and cardiac index:
.8  0.3 l/min/m2) were enrolled in this study.
Iron-deficient anemic patients were randomized to receive
ither the combination of subcutaneous darbepoetin alfa (DA) (50
g) with intravenous iron sucrose (300 mg) once weekly (group A,
 14), or intravenous iron alone (300 mg) once weekly (group B,
 16). A total amount of 1,800 mg of iron was administered.
uration of treatment was pre-specified to 6 weeks for both
roups. Iron sucrose was diluted in 100 ml of normal saline and
as administered slowly over 3 h through a peripheral vein. A test
ose of 25 mg of iron sucrose diluted in saline was infused before
he first full dose, to assess tolerance.
Values are reported as mean  SD. Differences in the baseline
haracteristics and Hgb values between the 2 groups were exam-
ned using the Student t test for unpaired observations (or
ann-Whitney test when the assumption of distribution normal-ty was violated). Differences in Hgb within each group, as well as
etween groups at different time points, were examined with
epeated measures 2-way analysis of variance (Bonferroni test for
ithin-treatment group comparisons at the different time points).
ean values of systolic arterial pressure, serum creatinine, Hgb,
ean corpuscular volume, and ferritin were 97.2  10.6 mm Hg
ersus 98.4  9.2 mm Hg, p  0.762; 1.3  0.5 mg/dl versus
.4  0.5 mg/dl, p  0.697; 10.6  0.9 g/dl versus 10.9  1.1
g/dl, p  0.420; 83  7.4 fl versus 86.7  7.7 fl, p  0.203; and
121.1  114.2 ng/ml versus 139.8  163.9 ng/ml, p  0.523, for
groups A and B, respectively.
A significant increase in Hgb was observed from baseline to the
sixth week of treatment and persisted to 3 months of follow-up
(Group A: from 10.6  0.9 g/dl to 12.8  1.4 g/dl, p  0.05, and
to 12.9  0.6 g/dl, p  0.05, respectively, and in Group B: from
10.9  1.1 g/dl to 12.6  0.8 g/dl, p  0.01, and 13.2  0.5 g/dl,
p  0.001, respectively. There was no difference in Hgb values
between the 2 groups at any time point (p 0.71), suggesting that
the combination of DA with intravenous iron does not correct
anemia faster or achieve higher Hgb levels compared with intra-
venous iron alone. Hgb values remained corrected and within the
optimal range of 12 to 14 g/dl at the end of the 3-month period of
follow-up (Fig. 1). No maintenance dose of either agent was
administered after the end of the active treatment period.
The main finding of this study is that intravenous iron alone is
as efficient as its combination with DA for the correction of anemia
secondary to ID in patients with advanced HF.
It is well established that iron improves patients’ clinical condition
in HF (3). However, our study is the first, to our knowledge, to
compare iron alone to erythropoietin plus iron in advanced HF
patients, with ID documented by bone marrow aspiration. The
rationale for combining ESA with iron, despite the fact that ID was
unequivocally demonstrated, was based on the unique pathophysio-
logical mechanisms of anemia in HF that could have blunted response
to iron alone and the need for rapid anemia correction in severely ill
patients. Our data document that at advanced stages of HF, when ID
is the underlying cause of anemia, intravenous iron alone is adequate
treatment. Simple blood sample indices that could accurately diagnose
ID in HF and negate the need for bone marrow aspiration would be
of profound value in everyday clinical practice.
The present study was not adequately powered to detect small
differences between groups or to compare the effect of anemia
correction with each 1 of these 2 therapeutic regimens on patients’
symptoms or prognosis. Larger studies with clinical outcome as the
primary endpoint are still needed. Only if anemia correction with
ESA is proven to favorably affect prognosis in this group of patients
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November 20/27, 2012:2255–60would the additional cost and risks of these agents be justified (4). In
addition, although we did not observe serious adverse effects of any
regimen, the study was not adequately powered to confirm equiva-
lence in safety of these treatment approaches.
In conclusion, monotherapy with intravenous iron should be regarded
as an efficient treatment option for ID in advanced stages of HF.
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Atrioventricular Valve Annular Remodeling
ChildrenTo the Editor: Atrioventricular (AV) valve repair for regurgitation has
been shown to be preferable to valve replacement in young children
(1). Besides valvuloplasty technique, annulus reduction and stabiliza-
tion with a ring have been demonstrated to be necessary to maintain
effective leaflet coaptation. In young children, however, placement of
a permanent annuloplasty ring is rarely performed because it carries
the risk that a re-operation will likely be required as the child grows.
The concept of annuloplasty with biodegradable material, as an
adjunct to AV valve repair, is not new. More recently, a flexible
intra-annular AV valve ring that is constructed of absorbable
biopolymer has been introduced for mitral valve (MV) and
tricuspid valve repair (2,3). Unlike rigid or semirigid rings, this
new device is a partial ring made of flexible material, which loses
tensile strength as the ring material absorbs, thus potentiallydata available on outcomes of absorbable ring implantation in
young children with complex congenital heart disease (CHD).
Six children (4 months to 8 years, median age: 5.4 years) with
CHD and severe AV valve regurgitation underwent AV valve
plasty and insertion of a biodegradable annuloplasty ring (Bioring
SA, Lonay, Switzerland). Four children had previously had AV
canal defect repair (2 had associated heterotaxy syndrome and 1
Shone’s complex), 1 a dysplastic MV, and another had hypoplastic
left heart syndrome. Food and Drug Administration approval for
device implantation was obtained for all patients under compas-
sionate use exemption. Institutional review board approval and
informed consent were obtained on all patients.
There were no perioperative deaths or complications such as AV
block or coronary compromise. By early post-operative echocardi-
ography, the AV valve anteroposterior (AP) and lateral diameters,
